Press release
Liposarcoma Pipeline Insight | Companies- Rain Therapeutics, Pfizer, Sanofi, Incyte Corporation, Macrogenics, Adaptimmune, Merck KGaA, GlaxoSmithKline, Novartis Oncology, Immune Design, and others
To explore more information on the latest breakthroughs in the Liposarcoma Pipeline treatment landscape of the report, click here @ Liposarcoma Pipeline Outlook- https://www.delveinsight.com/sample-request/liposarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Liposarcoma Pipeline Report
• Over 15+ Liposarcoma companies are evaluating 15+ Liposarcoma pipeline therapies in various stages of development, and their anticipated acceptance in the Liposarcoma market would significantly increase market revenue.
• The leading Liposarcoma Companies include Karyopharm Therapeutics, Rain Therapeutics, Pfizer, Sanofi, Incyte Corporation, Macrogenics, Adaptimmune, Merck KGaA, GlaxoSmithKline, Novartis Oncology, Immune Design, Syndivia, TerSera Therapeutics, and others.
• Promising Liposarcoma Pipeline Therapies include Trabectedin, Dexamethasone, Dacarbazine, RAIN-32, HDM201, LEE011, Selinexor, IPI-504, Yondelis, Cabazitaxel, MGCD516, and others.
• The Liposarcoma Companies and academics are working to assess challenges and seek opportunities that could influence Liposarcoma R&D. The Liposarcoma pipeline therapies under development are focused on novel approaches to treat/improve Liposarcoma.
For further information, refer to the detailed Liposarcoma Unmet Needs, Liposarcoma Market Drivers, and Liposarcoma Market Barriers, click here for Liposarcoma Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/liposarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Liposarcoma Overview
Liposarcomas are a rare type of malignant tumors of fatty tissue. They are the second most common type of soft-tissue sarcoma. Liposarcoma can occur in fat cells in any part of the body, but most cases occur in the muscles of the limbs or in the abdomen. Liposarcomas are typically found in adults, typically between the ages of 40 and 60, and are rare in children. Liposarcoma occurs more often in men than women. Liposarcoma risk factors may include radiation, family cancer syndromes, a damaged lymph system, and/or exposure to certain chemicals.
Request a sample and discover the recent advances in Liposarcoma Ongoing Clinical Trial Analysis and Medications, click here @ Liposarcoma Treatment Landscape- https://www.delveinsight.com/sample-request/liposarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Liposarcoma Emerging Drugs
• RAIN-32: Rain Therapeutics
RAIN-32 (milademetan) is a small molecule based oral inhibitor of mouse double minute 2 (MDM2). MDM2 is a critical regulator of tumor protein 53 (p53), which is known as the "guardian of the genome". RAIN-32 is in Phase III clinical studies for the treatment of Liposarcoma.
• Selinexor: Karyopharm Therapeutics
Selinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound. The molecule functions by binding with, and inhibiting, the nuclear export protein, XPO1, leading to the accumulation of tumor suppressor proteins in the cell nucleus. Selinexor, with the brand name XPOVIO, has been approved by the USFDA for relapsed or refractory multiple myeloma, relapsed or refractory diffuse large B-cell lymphoma (DLBCL), and in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The drug is in Phase III clinical studies for the treatment of Liposarcoma.
Dive deep into rich insights for drugs for Liposarcoma Market Drivers and Liposarcoma Market Barriers, click here @ Liposarcoma Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/liposarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Liposarcoma Pipeline Therapeutics Assessment
There are approx. 15+ Liposarcoma companies which are developing the Liposarcoma therapies. The Liposarcoma companies which have their Liposarcoma drug candidates in the most advanced stage, i.e. Phase III include, Rain Therapeutics.
Scope of the Liposarcoma Pipeline Report
• Coverage- Global
• Liposarcoma Companies- Karyopharm Therapeutics, Rain Therapeutics, Pfizer, Sanofi, Incyte Corporation, Macrogenics, Adaptimmune, Merck KGaA, GlaxoSmithKline, Novartis Oncology, Immune Design, Syndivia, TerSera Therapeutics, and others.
• Liposarcoma Pipeline Therapies- Trabectedin, Dexamethasone, Dacarbazine, RAIN-32, HDM201, LEE011, Selinexor, IPI-504, Yondelis, Cabazitaxel, MGCD516, and others.
• Liposarcoma Pipeline Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Liposarcoma Mergers and acquisitions, Liposarcoma Licensing Activities @ Liposarcoma Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/liposarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Liposarcoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Liposarcoma - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. RAIN-32: Rain Therapeutics
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Cabazitaxel: Sanofi
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. Ribociclib: Novartis Oncology
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. SDV-1101: Syndivia
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Liposarcoma Key Companies
21. Liposarcoma Key Products
22. Liposarcoma- Unmet Needs
23. Liposarcoma- Market Drivers and Barriers
24. Liposarcoma- Future Perspectives and Conclusion
25. Liposarcoma Analyst Views
26. Appendix
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Liposarcoma Pipeline Insight | Companies- Rain Therapeutics, Pfizer, Sanofi, Incyte Corporation, Macrogenics, Adaptimmune, Merck KGaA, GlaxoSmithKline, Novartis Oncology, Immune Design, and others here
News-ID: 3067832 • Views: …
More Releases from DelveInsight Business Research
Erectile Dysfunction Market Growth Outlook 2034: Epidemiology, Pipeline Therapie …
DelveInsight's "Erectile Dysfunction Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Erectile Dysfunction, historical and forecasted epidemiology as well as the Erectile Dysfunction market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Erectile Dysfunction market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Erectile Dysfunction Market Forecast
https://www.delveinsight.com/sample-request/erectile-dysfunction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav
Some of the…
Degenerative Disc Disease Pipeline 2026: FDA Approvals and Clinical Trials Lands …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Degenerative Disc Disease pipeline constitutes 15+ key companies continuously working towards developing 15+ Degenerative Disc Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Degenerative Disc Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase.…
Charcot Marie Tooth Disease Pipeline 2026: Therapies, MOA Insights, and Key Clin …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Charcot Marie Tooth Disease pipeline constitutes 13+ key companies continuously working towards developing 15+ Charcot Marie Tooth Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Charcot Marie Tooth Disease Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across…
Stargardt Disease Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Tria …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Stargardt Disease pipeline constitutes 20+ key companies continuously working towards developing 20+ Stargardt Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Stargardt Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also…
More Releases for Liposarcoma
Myxoid Round Cell Liposarcoma (MRCLS) Drug Market: An Overview
Myxoid Round Cell Liposarcoma (MRCLS) is a rare and aggressive form of cancer that arises from the fat cells of connective tissues. It primarily affects the soft tissues, including the limbs, trunk, and retroperitoneum, often leading to pain, swelling, and other debilitating symptoms. MRCLS is classified as a type of liposarcoma, a cancer that can appear in various forms, with the myxoid subtype being particularly distinct due to the presence…
Liposarcoma Market to Witness Growth by 2032, Estimates DelveInsight
DelveInsight's "Liposarcoma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Liposarcoma, historical and forecasted epidemiology as well as the Liposarcoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Liposarcoma market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Liposarcoma market size from 2019 to 2032, segmented…
Retroperitoneal Liposarcoma Treatment Market - Size, Outlook, and Opportunity An …
Retroperitoneal liposarcoma (RLS) is a rare, biologically heterogeneous cancer, which occurs in retroperitoneum, lining of the abdominal space that covers the abdominal organs. Retroperitoneal liposarcoma grow continuously and may not get diagnosed until they are very large thus, its prognosis is poor compared to the other subtypes of retroperitoneal sarcomas. The reason for the development of these tumors are still unknown, however, genetic mutation is considered to be one of…
Liposarcoma Treatment Market to Register Steady Growth During 2022
Liposarcoma is a cancer of fat cells lying deep within the soft tissues, typically in retroperitoneum or thighs. According to WHO, liposarcoma is the most common type of sarcomas (cancer of soft tissue) and accounts for approximately 17-20% of all cases of sarcoma. However, WHO classifies liposarcoma in the rare diseases as the incidence rate of the disease is as low as 2.5 per Mn population. Liposarcoma most commonly occurs…
Global Liposarcoma Treatment Market to Record Sturdy Growth by 2022
Liposarcoma is a cancer of fat cells lying deep within the soft tissues, typically in retroperitoneum or thighs. According to WHO, liposarcoma is the most common type of sarcomas (cancer of soft tissue) and accounts for approximately 17-20% of all cases of sarcoma. However, WHO classifies liposarcoma in the rare diseases as the incidence rate of the disease is as low as 2.5 per Mn population. Liposarcoma most commonly occurs…
Future of Global Liposarcoma Treatment Market 2016 - 2022
Liposarcoma is a cancer of fat cells lying deep within the soft tissues, typically in retroperitoneum or thighs. According to WHO, liposarcoma is the most common type of sarcomas (cancer of soft tissue) and accounts for approximately 17-20% of all cases of sarcoma. However, WHO classifies liposarcoma in the rare diseases as the incidence rate of the disease is as low as 2.5 per Mn population. Liposarcoma most commonly occurs…
